Moderna (MRNA) Stock Climbs Nearly 4% Following Melanoma Trial Success and Vaccine Approval

Moderna (MRNA) stock climbed 3.6% on melanoma vaccine trial success and COVID approval, but analysts remain cautious with $80.53 average price target.

The post Moderna (MRNA) Stock Climbs Nearly 4% Following Melanoma Trial Success and Vaccine Approval appeared first on Blockonomi.